Search

for
Search:

Research

5 / 1000+ results

research ONKOLOGIA OKULISTYCZNA WCZORAJ I DZIŚ

January 2024 in “Wiadomości Lekarskie”

This study reports that while primary treatment for uveal melanoma has a very high success rate, treating distant metastases, particularly in the liver, remains challenging. Tebentafusp, dependent on HLA-A expression, is the first drug to extend patient survival.

research In silico analysis of ethyl acetate Bruguiera gymnorhiza leaf extracts as an anti-inflammatory agent

4 citations , September 2024 in “Jurnal Pengolahan Hasil Perikanan Indonesia”

In this study, researchers reported that compounds from Bruguiera gymnorhiza leaves showed anti-inflammatory potential in in silico analyses, with favorable drug properties and specific binding to the IKKβ receptor, suggesting possible development into anti-inflammatory drugs.

research 882 Syndactyly type III and hypotrichosis in oculodentodigital syndrome with GJA1 mutation

April 2017 in “Journal of Investigative Dermatology”

This case study reports that a heterozygous missense GJA1 mutation, p.Gly138Ser, in a 2-year-old boy with oculodentodigital syndrome primarily resulted in syndactyly, fifth finger hypoplasia, and hypotrichosis, without neurological or craniofacial abnormalities.

research Actinic Keratosis: Risk Factors, Clinical, Diagnosis and Therapeutics Aspects. Part I

April 2024 in “Dermatovenerologiâ, kosmetologiâ”

This material provides comprehensive information about actinic keratosis, highlighting its potential outcomes, risk factors, clinical features, diagnosis, and treatment considerations for medical specialists.

research Actinic Keratosis: Risk Factors, Clinical, Diagnosis and Therapeutics Aspects. Part I

April 2024 in “Dermatovenerologiâ, kosmetologiâ”

This study provides a comprehensive overview of actinic keratosis, highlighting its potential to progress to squamous cell carcinoma and noting that routine treatment poses a significant burden on healthcare providers.

View more "protox iii" in research →

Community Join

1 / 1000+ results

community Waiting to start treatment until Kintor KX-826 Phase 2 data is published?

17 upvotes 4 years ago

People are waiting for KX-826 (Pyrilutamide) Phase 2 data to decide on hair loss treatments, with some considering finasteride or minoxidil in the meantime. Pyrilutamide is seen as a potentially stronger and safer alternative to finasteride, but concerns about side effects and availability remain.

View more "protox iii" in community →

Experts

3 / 3 results

Learn

— no results

Try a deeper search in learn →

Clinics

— no results

Try a deeper search in clinics →

Search

for
Search:

Research

research ONKOLOGIA OKULISTYCZNA WCZORAJ I DZIŚ

research In silico analysis of ethyl acetate Bruguiera gymnorhiza leaf extracts as an anti-inflammatory agent

research 882 Syndactyly type III and hypotrichosis in oculodentodigital syndrome with GJA1 mutation

research Actinic Keratosis: Risk Factors, Clinical, Diagnosis and Therapeutics Aspects. Part I

research Actinic Keratosis: Risk Factors, Clinical, Diagnosis and Therapeutics Aspects. Part I

Community Join

community Waiting to start treatment until Kintor KX-826 Phase 2 data is published?

Experts

Dr. Joseph F. Greco III, MD

Joseph M. Dai III, MD

Dr. William P. Coleman III, MD

Learn

Clinics